Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDT vs NIVF: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDT Captures Overall Composite Edge (31.6 SELL vs 47.7 HOLD), While NIVF Leads 2–1 on Growth & Valuation Pillars

CDT Overall Winner 6-Pillar Tally: CDT 1 – 2 NIVF (3 Tie) Matrix Metrics: CDT 3 – 4 NIVF

As of Nov 20, 2026, CDT Equity Inc. (CDT) captures the overall head-to-head institutional edge over NewGenIvf Group Limited Class A (NIVF) on higher Unified Composite conviction (31.6/100 SELL vs. 47.7/100 HOLD) after splitting the core matrix 3–4 (led by Growth & Scale), while NIVF wins 2–1 across the 6-pillar growth and valuation breakdown. CDT trades at $0.23 (N/M Forward P/E, 0.0% operating margin) versus NIVF at $0.03 (N/M Forward P/E, -238.2% operating margin).

  • Composite vs. Pillar Nuance: While NIVF currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. CDT 31.6/100 SELL), CDT captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -238.2% operating margin) and revenue trajectory (+0.0% vs. -4.7% YoY).
  • Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDT vs NIVF
CDT NASDAQ Head-to-Head Winner
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40
NIVF NASDAQ
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.03
-23.14% 1D
Market Cap $98,000
TTM Revenue $4.6M
Forward P/E N/M
Beta / 30D Vol 0.05β · 3040% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.9%), weak momentum, RSI 33
RSI-14: 32.9 · SMA20: $0.56 · SMA50: $0.46

6-Pillar Scorecard Institutional Category Breakdown (CDT 1 – 2 NIVF)

Columns: Metric · CDT · NIVF
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CDT
Revenue Growth (YoY) +0.0% -4.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.6M
Market Cap $507,528 $98,000
3. Profitability & Quality NIVF
Gross Margin N/A 23.9%
Operating Margin 0.0% -238.2%
Net Profit Margin 0.0% 24.2%
Return on Equity (ROE) -69.7% 5.5%
4. Balance Sheet & Cash Flow NIVF
Cash Generation (TTM) N/A -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $435,000 Net Debt (0.01x D/E) $733.75 Book/Sh · 5.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDT (3) vs NIVF (4)
Institutional Metric CDT NIVF Criterion Row Edge
Market Capitalization
Scale
$507,528 $98,000 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -4.7% Higher Growth CDT
Operating Margin (TTM)
Profitability
0.0% -238.2% Higher Margin CDT
Net Profit Margin
Profitability
0.0% 24.2% Higher Margin NIVF
Return on Equity (ROE)
Capital Efficiency
-69.7% 5.5% Higher ROE NIVF
52-Week Range Position
Momentum
2% ($0–$11) 0% ($0–$3) Stronger Trend CDT
Beta / 30D Volatility
Risk Regime
-17.75β · 10175% Vol 0.05β · 3040% Vol Lower Realized Risk NIVF
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 47.7 / 100 (HOLD) Higher Composite NIVF
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 23.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($435,000 Net Debt (0.01x D/E)) -$11M EBITDA ($733.75 Book/Sh · 5.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +158.72 pp
CDT: +76.79% · NIVF: -81.93%
3M Horizon CDT +3.8 pp
CDT: -90.76% · NIVF: -94.56%
6M Horizon CDT +19.26 pp
CDT: -78.1% · NIVF: -97.36%
1Y Horizon CDT +5.04 pp
CDT: -86.78% · NIVF: -91.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs NIVF. Trailing 12-month operating profitability (CDT 0.0% vs NIVF -238.2%) and valuation multiples (CDT N/M vs NIVF N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M
NIVF ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.6M
Gross Margin23.9%
Op. Margin-238.2%
ROE / Fwd P/E5.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NIVF BREAKDOWN
19d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NIVF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NIVF Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $98,000 market capitalization and -238.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDT vs NIVF Key Questions & Quantitative Answers

As of Nov 20, 2026, CDT Equity Inc. (CDT) captures the overall head-to-head institutional edge over NewGenIvf Group Limited Class A (NIVF) on higher Unified Composite conviction (31.6/100 SELL vs. 47.7/100 HOLD) after splitting the core matrix 3–4 (led by Growth & Scale), while NIVF wins 2–1 across the 6-pillar growth and valuation breakdown. CDT trades at $0.23 (N/M Forward P/E, 0.0% operating margin) versus NIVF at $0.03 (N/M Forward P/E, -238.2% operating margin). Composite vs. Pillar Nuance: While NIVF currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. CDT 31.6/100 SELL), CDT captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -238.2% operating margin) and revenue trajectory (+0.0% vs. -4.7% YoY). Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDT leads the Growth & Scale pillar: CDT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NIVF at -4.7% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (23.9% gross margin, -238.2% operating margin). On trailing 12-month operating scale, CDT generates N/A in USD-normalized revenue versus $4.6M for NIVF. In operating R&D and SG&A reinvestment, CDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NIVF.

CDT and NIVF trade at balanced relative valuation multiples. CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NIVF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDT (-69.7% ROE) versus NIVF (5.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk). By comparison, NIVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.05β · 3040% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.